| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Other Events Interactive Data |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/17/2023 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 06/12/2023 |
8-K
| Other Events Interactive Data |
| 05/30/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/26/2023 |
SC 13D/A
| Frazier Life Sciences Public Fund, L.P. reports a 18.5% stake in Phathom Pharmaceuticals, Inc. |
| 05/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among Phathom Pharmaceuticals, Inc. and Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP",
"Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock Florham Park, N.J., May 23, 2023 - Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Phathom intends to use the net proceeds from the proposed offer...",
"Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock Florham Park, N.J., May 23, 2023 - Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130.7 million. In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 1,668,750 shares of common stock at the public offering price, less underwriting discounts and commiss..." |
|
| 05/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/23/2023 |
8-K
| Other Events Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
SC 13D/A
| Frazier Life Sciences Public Fund, L.P. reports a 19.3% stake in Phathom Pharmaceuticals, Inc. |
| 04/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/04/2023 |
8-K
| Other Events Interactive Data |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/09/2023 |
SC 13G
| Carlyle Group Inc. reports a 6.7% stake in Phathom Pharmaceuticals, Inc. |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4.6% stake in Phathom Pharmaceuticals, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
8-K
| Other Events Interactive Data |
| 02/09/2023 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 0% stake in PHATHOM PHARMACEUTICALS, INC. |
| 02/02/2023 |
SC 13G/A
| Invesco Ltd. reports a 5.3% stake in Phathom Pharmaceuticals Inc |
| 01/31/2023 |
SC 13G/A
| Medicxi Growth I LP reports a 6% stake in Phathom Pharmaceuticals, Inc. |
| 01/09/2023 |
8-K
| Other Events Interactive Data |
| 01/03/2023 |
8-K
| Other Events Interactive Data |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q/A
| Quarterly Report for the period ended September 30, 2022 [amend] |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
|